KIT and Melanoma: Biological Insights and Clinical Implications
Duc Minh Pham, Samantha Guhan, Hensin Tsao
Abstract
mutations with clinicopathologic features (age, sex, melanoma subtypes, anatomic location, etc.), and the differences of mutation rate among subgroups. Finally, several therapeutic trials of c-KIT inhibitors, including imatinib, dasatinib, nilotinib, and sunitinib, will be analyzed for their success rates and limitations in advanced melanoma treatment. These not only emphasize c-KIT as an attractive target for personalized melanoma therapy but also propose the requirement for additional investigational studies to develop novel therapeutic trials co-targeting c-KIT and other cytokines such as members of signaling pathways and immune systems.
Topics & Concepts
Receptor tyrosine kinaseBiologyTyrosine kinaseStem cell factorMolecular biologyTransmembrane proteinProtein kinase domainProto-Oncogene Proteins c-kitTransmembrane domainCell biologyReceptorKinaseBiochemistrySignal transductionProgenitor cellStem cellGeneMutantMast cells and histaminePlatelet Disorders and TreatmentsCell Adhesion Molecules Research